<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Behav Brain Funct</journal-id><journal-title>Behavioral and brain functions : BBF</journal-title><issn pub-type="epub">1744-9081</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1744-9081-1-15</article-id><article-id pub-id-type="pmid">16131404</article-id><article-id pub-id-type="doi">10.1186/1744-9081-1-15</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Association study of polymorphisms in synaptic vesicle-associated genes, <italic>SYN2 </italic>and <italic>CPLX2</italic>, with schizophrenia</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Lee</surname><given-names>Hee Jae</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I4">4</xref><email>heejaelee@kangwon.ac.kr</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Song</surname><given-names>Ji Young</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>jysongnp@hanmail.net</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Kim</surname><given-names>Jong Woo</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>psyjongwoo@freechal.com</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Jin</surname><given-names>Sheng-Yu</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>kimshengyu@hanmail.net</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Hong</surname><given-names>Mi Suk</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>msbona21@korea.com</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Park</surname><given-names>Jin Kyoung</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>dasom39@unitel.co.kr</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Chung</surname><given-names>Joo-Ho</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>jhchung@khu.ac.kr</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Shibata</surname><given-names>Hiroki</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>hshibata@gen.kyushu-u.ac.jp</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Fukumaki</surname><given-names>Yasuyuki</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>yfukumak@gen.kyushu-u.ac.jp</email></contrib></contrib-group><aff id="I1"><label>1</label>Medical Science Institute, Kangwon National University, Chunchon, Republic of Korea</aff><aff id="I2"><label>2</label>Department of Neuropsychiatry, College of Medicine, Kyung Hee University, Seoul, Republic of Korea</aff><aff id="I3"><label>3</label>Kohwang Medical Research Institute, College of Medicine, Kyung Hee University, Seoul, Republic of Korea</aff><aff id="I4"><label>4</label>Division of Disease Genes, Research Center for Genetic Information, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan</aff><pub-date pub-type="collection"><year>2005</year></pub-date><pub-date pub-type="epub"><day>31</day><month>8</month><year>2005</year></pub-date><volume>1</volume><fpage>15</fpage><lpage>15</lpage><ext-link ext-link-type="uri" xlink:href="http://www.behavioralandbrainfunctions.com/content/1/1/15"/><history><date date-type="received"><day>28</day><month>6</month><year>2005</year></date><date date-type="accepted"><day>31</day><month>8</month><year>2005</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2005 Lee et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2005</copyright-year><copyright-holder>Lee et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Lee Hee Jae heejaelee@kangwon.ac.kr </dc:author><dc:title> Association study of polymorphisms in synaptic vesicle-associated genes, SYN2 and CPLX2, with schizophrenia </dc:title><dc:date>2005</dc:date><dcterms:bibliographicCitation>Behavioral and Brain Functions 1(1): 15-. (2005)</dcterms:bibliographicCitation><dc:identifier type="sici">1744-9081(2005)1:1&#x0003c;15&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1744-9081</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>The occurrence of aberrant functional connectivity in the neuronal circuit is one of the integrative theories of the etiology of schizophrenia. Previous studies have reported that the protein and mRNA levels of the synapsin 2 (<italic>SYN2</italic>) and complexin 2 (<italic>CPLX2</italic>) genes were decreased in patients with schizophrenia. Synapsin 2 and complexin 2 are involved in synaptogenesis and the modulation of neurotransmitter release. This report presents a study of the association of polymorphisms of <italic>SYN2 </italic>and <italic>CPLX2 </italic>with schizophrenia in the Korean population.</p></sec><sec sec-type="methods"><title>Methods</title><p>Six single nucleotide polymorphisms (SNPs) and one 5-bp insertion/deletion in <italic>SYN2 </italic>and five SNPs in <italic>CPLX2 </italic>were genotyped in 154 Korean patients with schizophrenia and 133 control patients using direct sequencing or restriction fragment length polymorphism analysis. An intermarker linkage disequilibrium map was constructed for each gene.</p></sec><sec><title>Results</title><p>Although there was no significant difference in the genotypic distributions and allelic frequencies of either <italic>SYN2 </italic>or <italic>CPLX2 </italic>polymorphisms between the schizophrenia and control groups, the two-way haplotype analyses revealed significant associations with the disease (<italic>P </italic>&#x0003c; 0.05 after Bonferroni correction). The three-way haplotype analyses also revealed a significant association of <italic>SYN2 </italic>with schizophrenia (<italic>P </italic>&#x0003c; 0.001 after Bonferroni correction).</p></sec><sec><title>Conclusion</title><p>These results suggest that both <italic>SYN2 </italic>and <italic>CPLX2 </italic>may confer susceptibility to schizophrenia in the Korean population.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Schizophrenia is a severe, chronic mental illness affecting 0.5&#x02013;1.5% of the general population worldwide [<xref ref-type="bibr" rid="B1">1</xref>]. The contribution of genetic factors to the vulnerability to schizophrenia has been well established by family, twin, and adoption studies that have suggested a significant heritability of approximately 50&#x02013;70% [<xref ref-type="bibr" rid="B2">2</xref>]. Many studies have attempted to identify the allelic variants that confer susceptibility to the illness, but no single genes have been identified that produce a major effect on the vulnerability [<xref ref-type="bibr" rid="B3">3</xref>].</p><p>Recently the synaptic hypothesis of schizophrenia has gained attention by attributing the fundamental pathology of schizophrenia to the dysfunction of synaptic transmission involving various molecules [<xref ref-type="bibr" rid="B4">4</xref>]. Synapsins, a family of synaptic vesicle-associated phosphoproteins, play a crucial role in the regulation of neurotransmission, synaptogenesis, and neuronal plasticity [<xref ref-type="bibr" rid="B5">5</xref>]. Three human synapsin genes have been identified (<italic>SYN1</italic>, <italic>2</italic>, and <italic>3</italic>; OMIM 313440, 600755, and 602705) [<xref ref-type="bibr" rid="B6">6</xref>]. Complexin 1 and complexin 2, which are encoded by <italic>CPLX1 </italic>(OMIM 605032) and <italic>CPLX2 </italic>(OMIM 605033), respectively, and are also called synaphins, are pre-synaptic membrane proteins that preferentially bind to syntaxin within the SNARE (soluble N-ethylmaleimide-sensitive fusion attachment protein receptors) complex. These proteins are important regulators of transmitter release immediately preceding vesicle fusion [<xref ref-type="bibr" rid="B7">7</xref>]. Previous studies have demonstrated that the concentrations of synapsins and complexins are reduced in the brains of schizophrenics [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. The expression levels of both synapsins were significantly decreased in the hippocampal tissue of schizophrenic patients [<xref ref-type="bibr" rid="B10">10</xref>]. The levels of synapsin 2 and complexin 2 mRNA were also significantly reduced in the prefrontal cortex, cerebellum, and hippocampus of schizophrenics [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B14">14</xref>].</p><p><italic>SYN2 </italic>was mapped to chromosome 3p25 [<xref ref-type="bibr" rid="B15">15</xref>], and <italic>CPLX2 </italic>is located on chromosome 5q35.3 (OMIM 605033). These loci were identified as potential regions conferring susceptibility to schizophrenia in diverse populations [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B18">18</xref>]. Based on their localization, well-established neurobiological roles, and expression patterns in schizophrenic patients, we selected <italic>SYN2 </italic>and <italic>CPLX2 </italic>as candidate genes for conferring susceptibility to schizophrenia. In this report, we present an association study of <italic>SYN2 </italic>and <italic>CPLX2 </italic>with schizophrenia using 12 polymorphisms in the Korean population.</p></sec><sec><title>Results</title><sec><title><italic>SYN2 </italic>polymorphisms in the schizophrenia and control groups</title><p>Of the seven polymorphisms in <italic>SYN2</italic>, rs2623873 (SYN2-1) is located in the promoter region, whereas the others are all located in the intronic regions (SYN2-2&#x02013;7) (Fig. <xref ref-type="fig" rid="F1">1</xref>, Table <xref ref-type="table" rid="T1">1</xref>). The genotypic distributions and allelic frequencies of polymorphisms in <italic>SYN2 </italic>were determined in 113 schizophrenic patients and 114 normal healthy controls by direct sequencing or <italic>Dde</italic>I RFLP. The genotypic distributions and allelic frequencies of polymorphisms in <italic>SYN2 </italic>are shown in Table <xref ref-type="table" rid="T2">2</xref>. The average allelic frequency of the SNPs was 0.312. Given the equivalent frequency for the susceptible allele, the expected detection power for <italic>SYN2 </italic>was 0.9538 to 0.9929 under the multiplicative model with a genotype relative risk = 1.8 to 2.0 [<xref ref-type="bibr" rid="B22">22</xref>]. None of the SNPs showed any significant deviation from Hardy-Weinberg equilibrium (<italic>P </italic>&#x0003e; 0.05). We observed no significant difference in the genotypic distributions and allelic frequencies between the schizophrenics and control groups (Table <xref ref-type="table" rid="T2">2</xref>).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Genomic organization of <italic>SYN2 </italic>and <italic>CPLX2 </italic>and locations of SNPs</bold>. <bold>a</bold>; <italic>SYN2 </italic>spans over 140 kb and is composed of 14 exons. Seven markers are indicated with the dbSNP reference ID <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP"/>. <bold>b</bold>; <italic>CPLX2 </italic>spans over 83 kb and is composed 3 exons. Five markers are indicated with the dbSNP reference ID <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP"/>.</p></caption><graphic xlink:href="1744-9081-1-15-1"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Twelve polymorphisms genotyped in this study.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Gene</td><td align="left">Name</td><td align="left">dbSNP rs#</td><td align="left">Region</td><td align="left">Allele</td><td align="left">Methods</td></tr></thead><tbody><tr><td align="left"><italic>SYN2</italic></td><td align="left">SYN2-1</td><td align="left">rs2623873</td><td align="left">Promoter</td><td align="left">G/T</td><td align="left">Direct Sequencing</td></tr><tr><td align="left"><italic>SYN2</italic></td><td align="left">SYN2-2</td><td align="left">rs2308169</td><td align="left">Intron</td><td align="left">ATGCT/-</td><td align="left">Direct Sequencing</td></tr><tr><td align="left"><italic>SYN2</italic></td><td align="left">SYN2-3</td><td align="left">rs308961</td><td align="left">Intron</td><td align="left">T/G</td><td align="left">Direct Sequencing</td></tr><tr><td align="left"><italic>SYN2</italic></td><td align="left">SYN2-4</td><td align="left">rs308963</td><td align="left">Intron</td><td align="left">C/G</td><td align="left">Direct Sequencing</td></tr><tr><td align="left"><italic>SYN2</italic></td><td align="left">SYN2-5</td><td align="left">rs308952</td><td align="left">Intron<sup>a</sup></td><td align="left">A/G</td><td align="left"><italic>Dde</italic>I RFLP</td></tr><tr><td align="left"><italic>SYN2</italic></td><td align="left">SYN2-6</td><td align="left">rs2279750</td><td align="left">Intron<sup>a</sup></td><td align="left">A/C</td><td align="left">Direct Sequencing</td></tr><tr><td align="left"><italic>SYN2</italic></td><td align="left">SYN2-7</td><td align="left">rs310762</td><td align="left">Intron</td><td align="left">C/T</td><td align="left">Direct Sequencing</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left"><italic>CPLX2</italic></td><td align="left">CPLX2-1</td><td align="left">rs2247916</td><td align="left">Promoter</td><td align="left">G/T</td><td align="left"><italic>Mae</italic>III RFLP</td></tr><tr><td align="left"><italic>CPLX2</italic></td><td align="left">CPLX2-2</td><td align="left">rs2243404</td><td align="left">5'UTR</td><td align="left">C/T</td><td align="left"><italic>Cac</italic>8I RFLP</td></tr><tr><td align="left"><italic>CPLX2</italic></td><td align="left">CPLX2-3</td><td align="left">rs890736</td><td align="left">Intron</td><td align="left">C/T</td><td align="left"><italic>Ava</italic>II RFLP</td></tr><tr><td align="left"><italic>CPLX2</italic></td><td align="left">CPLX2-4</td><td align="left">rs890737</td><td align="left">Intron</td><td align="left">C/T</td><td align="left">Direct Sequencing</td></tr><tr><td align="left"><italic>CPLX2</italic></td><td align="left">CPLX2-5</td><td align="left">rs4390706</td><td align="left">Intron</td><td align="left">G/A</td><td align="left">Direct Sequencing</td></tr></tbody></table><table-wrap-foot><p><sup>a </sup>Tissue inhibitor of metalloproteinase 4 (<italic>Timp4</italic>) gene is nested within the intron of <italic>SYN2 </italic>in reverse orientation.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Genotype distributions and allele frequencies of each polymorphism of the <italic>SYN2 </italic>and <italic>CPLX2 </italic>in the schizophrenia and control groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Polymorphism</td><td align="left">Subjects</td><td align="center" colspan="3">Genotype distribution (frequency)</td><td></td><td align="center" colspan="2">Allele frequency</td><td></td></tr><tr><td></td><td></td><td align="left">11</td><td align="left">12</td><td align="left">22</td><td align="left"><italic>P</italic><sup><italic>a</italic></sup></td><td align="left">1</td><td align="left">2</td><td align="left"><italic>P</italic><sup><italic>b</italic></sup></td></tr></thead><tbody><tr><td align="left">SYN2-1</td><td align="left">Cases (n = 113)</td><td align="left">47 (0.416)</td><td align="left">50 (0.442)</td><td align="left">16 (0.142)</td><td align="left">0.527</td><td align="left">0.637</td><td align="left">0.363</td><td align="left">0.679</td></tr><tr><td></td><td align="left">Controls (n = 114)</td><td align="left">41 (0.360)</td><td align="left">59 (0.518)</td><td align="left">14 (0.122)</td><td></td><td align="left">0.618</td><td align="left">0.382</td><td></td></tr><tr><td align="left">SYN2-2</td><td align="left">Cases (n = 113)</td><td align="left">40 (0.354)</td><td align="left">55 (0.487)</td><td align="left">18 (0.159)</td><td align="left">0.758</td><td align="left">0.597</td><td align="left">0.403</td><td align="left">0.438</td></tr><tr><td></td><td align="left">Controls (n = 114)</td><td align="left">36 (0.316)</td><td align="left">56 (0.491)</td><td align="left">22 (0.193)</td><td></td><td align="left">0.561</td><td align="left">0.439</td><td></td></tr><tr><td align="left">SYN2-3</td><td align="left">Cases (n = 113)</td><td align="left">83 (0.735)</td><td align="left">30 (0.265)</td><td align="left">0 (0.000)</td><td align="left">0.762</td><td align="left">0.867</td><td align="left">0.133</td><td align="left">0.975</td></tr><tr><td></td><td align="left">Controls (n = 114)</td><td align="left">85 (0.746)</td><td align="left">28 (0.246)</td><td align="left">1 (0.009)</td><td></td><td align="left">0.868</td><td align="left">0.132</td><td></td></tr><tr><td align="left">SYN2-4</td><td align="left">Cases (n = 113)</td><td align="left">49 (0.434)</td><td align="left">45 (0.398)</td><td align="left">19 (0.168)</td><td align="left">0.722</td><td align="left">0.633</td><td align="left">0.367</td><td align="left">0.612</td></tr><tr><td></td><td align="left">Controls (n = 114)</td><td align="left">44 (0.386)</td><td align="left">51 (0.447)</td><td align="left">19 (0.167)</td><td></td><td align="left">0.610</td><td align="left">0.390</td><td></td></tr><tr><td align="left">SYN2-5</td><td align="left">Cases (n = 113)</td><td align="left">72 (0.637)</td><td align="left">35 (0.310)</td><td align="left">6 (0.053)</td><td align="left">0.973</td><td align="left">0.792</td><td align="left">0.208</td><td align="left">0.869</td></tr><tr><td></td><td align="left">Controls (n = 114)</td><td align="left">74 (0.649)</td><td align="left">34 (0.298)</td><td align="left">6 (0.053)</td><td></td><td align="left">0.798</td><td align="left">0.202</td><td></td></tr><tr><td align="left">SYN2-6</td><td align="left">Cases (n = 113)</td><td align="left">67 (0.593)</td><td align="left">39 (0.345)</td><td align="left">7 (0.062)</td><td align="left">0.786</td><td align="left">0.765</td><td align="left">0.235</td><td align="left">0.622</td></tr><tr><td></td><td align="left">Controls (n = 114)</td><td align="left">63 (0.553)</td><td align="left">44 (0.386)</td><td align="left">7 (0.061)</td><td></td><td align="left">0.746</td><td align="left">0.254</td><td></td></tr><tr><td align="left">SYN2-7</td><td align="left">Cases (n = 113)</td><td align="left">39 (0.345)</td><td align="left">54 (0.478)</td><td align="left">20 (0.177)</td><td align="left">0.847</td><td align="left">0.584</td><td align="left">0.416</td><td align="left">0.576</td></tr><tr><td></td><td align="left">Controls (n = 114)</td><td align="left">42 (0.368)</td><td align="left">55 (0.482)</td><td align="left">17 (0.149)</td><td></td><td align="left">0.610</td><td align="left">0.390</td><td></td></tr><tr><td colspan="9"><hr></hr></td></tr><tr><td align="left">CPLX2-1</td><td align="left">Cases (n = 154)</td><td align="left">132 (0.857)</td><td align="left">22 (0.143)</td><td align="left">0 (0.000)</td><td align="left">0.441</td><td align="left">0.929</td><td align="left">0.071</td><td align="left">0.612</td></tr><tr><td></td><td align="left">Controls (n = 133)</td><td align="left">113 (0.850)</td><td align="left">18 (0.135)</td><td align="left">2 (0.015)</td><td></td><td align="left">0.917</td><td align="left">0.083</td><td></td></tr><tr><td align="left">CPLX2-2</td><td align="left">Cases (n = 154)</td><td align="left">132 (0.857)</td><td align="left">22 (0.143)</td><td align="left">0 (0.000)</td><td align="left">0.254</td><td align="left">0.929</td><td align="left">0.071</td><td align="left">0.198</td></tr><tr><td></td><td align="left">Controls (n = 133)</td><td align="left">108 (0.812)</td><td align="left">23 (0.173)</td><td align="left">2 (0.015)</td><td></td><td align="left">0.898</td><td align="left">0.102</td><td></td></tr><tr><td align="left">CPLX2-3</td><td align="left">Cases (n = 154)</td><td align="left">115 (0.747)</td><td align="left">34 (0.221)</td><td align="left">5 (0.032)</td><td align="left">0.129</td><td align="left">0.857</td><td align="left">0.143</td><td align="left">0.072</td></tr><tr><td></td><td align="left">Controls (n = 133)</td><td align="left">85 (0.639)</td><td align="left">43 (0.323)</td><td align="left">5 (0.038)</td><td></td><td align="left">0.801</td><td align="left">0.199</td><td></td></tr><tr><td align="left">CPLX2-4</td><td align="left">Cases (n = 154)</td><td align="left">110 (0.714)</td><td align="left">40 (0.260)</td><td align="left">4 (0.026)</td><td align="left">1.000</td><td align="left">0.844</td><td align="left">0.156</td><td align="left">0.849</td></tr><tr><td></td><td align="left">Controls (n = 133)</td><td align="left">94 (0.707)</td><td align="left">35 (0.263)</td><td align="left">4 (0.030)</td><td></td><td align="left">0.838</td><td align="left">0.162</td><td></td></tr><tr><td align="left">CPLX2-5</td><td align="left">Cases (n = 154)</td><td align="left">124 (0.805)</td><td align="left">30 (0.195)</td><td align="left">0 (0.000)</td><td align="left">0.312</td><td align="left">0.903</td><td align="left">0.097</td><td align="left">0.541</td></tr><tr><td></td><td align="left">Controls (n = 133)</td><td align="left">112 (0.842)</td><td align="left">20 (0.150)</td><td align="left">1 (0.008)</td><td></td><td align="left">0.917</td><td align="left">0.083</td><td></td></tr></tbody></table><table-wrap-foot><p><sup>a </sup>Fisher's exact probability tests, case <italic>vs </italic>controls (2 &#x000d7; 3 genotype-based analysis)</p><p><sup>b </sup>Fisher's exact probability tests, case <italic>vs </italic>controls (2 &#x000d7; 2 allele-based analysis)</p></table-wrap-foot></table-wrap><p>We compared the LD for all possible two-way comparisons of the SNPs in the controls (Table <xref ref-type="table" rid="T3">3</xref>). The pairwise D' values for the seven SNPs were consistently high, except in one instance (SYN2-2 <italic>vs</italic>. SYN2-6; D' = 0.300, r<sup>2 </sup>= 0.200). Out of the 21 possible pairs of SNPs, significant haplotype associations with schizophrenia were observed for 4 pairs: SYN2-1 &#x02013; SYN2-2 (&#x003c7;<sup>2 </sup>= 27.58, df = 3, <italic>P </italic>= 4.45 &#x000d7; 10<sup>-6</sup>), SYN2-2 &#x02013; SYN2-4 (&#x003c7;<sup>2 </sup>= 16.46, df = 3, <italic>P </italic>= 9.12 &#x000d7; 10<sup>-4</sup>), SYN2-2 &#x02013; SYN2-7 (&#x003c7;<sup>2 </sup>= 8.08, df = 3, <italic>P </italic>= 0.044), and SYN2-3 &#x02013; SYN2-4 (&#x003c7;<sup>2 </sup>= 10.66, df = 3, <italic>P </italic>= 0.014) (Table <xref ref-type="table" rid="T3">3</xref>). Even after the Bonferroni correction (number of haplotypes, n = 21), the associations of the SYN2-1 &#x02013; SYN2-2 and SYN2-2 &#x02013; SYN2-4 haplotypes with schizophrenia remained significant (<italic>P</italic><sub><italic>corr </italic></sub>= 9.35 &#x000d7; 10<sup>-5 </sup>and <italic>P</italic><sub><italic>corr </italic></sub>= 0.019) (Table <xref ref-type="table" rid="T3">3</xref>). The T allele-the deletion allele haplotype for the SYN2-1 &#x02013; SYN2-2 combination and the deletion allele-the G allele haplotype for the SYN2-2 &#x02013; SYN2-4 combination were observed more frequently in schizophrenia than the controls (Table <xref ref-type="table" rid="T4">4</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Pairwise linkage disequilibrium and haplotype association of SNPs in <italic>SYN2</italic>.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><bold>SYN2-1</bold></td><td align="left"><bold>SYN2-2</bold></td><td align="left"><bold>SYN2-3</bold></td><td align="left"><bold>SYN2-4</bold></td><td align="left"><bold>SYN2-5</bold></td><td align="left"><bold>SYN2-6</bold></td><td align="left"><bold>SYN2-7</bold></td></tr></thead><tbody><tr><td align="left"><bold>SYN2-1</bold></td><td></td><td align="left">0.532</td><td align="left">0.776</td><td align="left">0.758</td><td align="left">0.865</td><td align="left">0.516</td><td align="left">0.642</td></tr><tr><td></td><td></td><td align="left">0.222</td><td align="left">0.056</td><td align="left">0.553</td><td align="left">0.306</td><td align="left">0.482</td><td align="left">0.397</td></tr><tr><td align="left"><bold>SYN2-2</bold></td><td align="left"><bold>4.45 &#x000d7; 10<sup>-6 a</sup></bold></td><td></td><td align="left">0.613</td><td align="left">0.453</td><td align="left">0.734</td><td align="left">0.300</td><td align="left">0.429</td></tr><tr><td></td><td></td><td></td><td align="left">0.044</td><td align="left">0.250</td><td align="left">0.174</td><td align="left">0.200</td><td align="left">0.225</td></tr><tr><td align="left"><bold>SYN2-3</bold></td><td align="left">0.246</td><td align="left">0.632</td><td></td><td align="left">1.000</td><td align="left">0.997</td><td align="left">0.480</td><td align="left">1.000</td></tr><tr><td></td><td></td><td></td><td></td><td align="left">0.097</td><td align="left">0.038</td><td align="left">0.433</td><td align="left">0.097</td></tr><tr><td align="left"><bold>SYN2-4</bold></td><td align="left">0.845</td><td align="left"><bold>9.12 &#x000d7; 10<sup>-4 a</sup></bold></td><td align="left">0.014</td><td></td><td align="left">1.000</td><td align="left">0.480</td><td align="left">0.806</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td align="left">0.395</td><td align="left">0.433</td><td align="left">0.650</td></tr><tr><td align="left"><bold>SYN2-5</bold></td><td align="left">0.896</td><td align="left">0.655</td><td align="left">0.135</td><td align="left">0.133</td><td></td><td align="left">0.938</td><td align="left">0.865</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td align="left">0.651</td><td align="left">0.295</td></tr><tr><td align="left"><bold>SYN2-6</bold></td><td align="left">0.116</td><td align="left">0.892</td><td align="left">0.602</td><td align="left">0.602</td><td align="left">0.147</td><td></td><td align="left">0.722</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td align="left">0.278</td></tr><tr><td align="left"><bold>SYN2-7</bold></td><td align="left">0.646</td><td align="left">0.044</td><td align="left">0.155</td><td align="left">0.392</td><td align="left">0.404</td><td align="left">0.0.72</td><td></td></tr></tbody></table><table-wrap-foot><p>Upper diagonal top: D', bottom: r<sup>2 </sup>in controls; Lower diagonal: <italic>P </italic>value by <italic>&#x003c7;</italic><sup>2 </sup>test (df = 3)</p><p><sup>a </sup><italic>P </italic>&#x0003c; 0.05 after Bonferroni correction</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Estimated haplotype frequencies of the SYN2-1 &#x02013; SYN2-2 and SYN2-2 &#x02013; SYN2-4 combination on the <italic>SYN2</italic></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Haplotypes</bold></td><td></td><td align="left" colspan="2"><bold>Estimated frequency</bold></td></tr></thead><tbody><tr><td align="left"><bold>SYN2-1</bold></td><td align="left"><bold>SYN2-2</bold></td><td align="left"><bold>Cases</bold></td><td align="left"><bold>Controls</bold></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">T</td><td align="left">Deletion</td><td align="left">0.583</td><td align="left">0.461</td></tr><tr><td align="left">T</td><td align="left">ATGCT</td><td align="left">0.054</td><td align="left">0.158</td></tr><tr><td align="left">G</td><td align="left">Deletion</td><td align="left">0.014</td><td align="left">0.100</td></tr><tr><td align="left">G</td><td align="left">ATGCT</td><td align="left">0.349</td><td align="left">0.281</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left"><bold>SYN2-2</bold></td><td align="left"><bold>SYN2-4</bold></td><td align="left"><bold>Cases</bold></td><td align="left"><bold>Controls</bold></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">Deletion</td><td align="left">G</td><td align="left">0.569</td><td align="left">0.463</td></tr><tr><td align="left">Deletion</td><td align="left">C</td><td align="left">0.028</td><td align="left">0.098</td></tr><tr><td align="left">ATGCT</td><td align="left">G</td><td align="left">0.064</td><td align="left">0.146</td></tr><tr><td align="left">ATGCT</td><td align="left">C</td><td align="left">0.339</td><td align="left">0.293</td></tr></tbody></table></table-wrap><p>We also investigated the association of three-way haplotypes formed by SYN2-1, SYN2-2, and SYN2-4 with schizophrenia. A significant difference in the haplotype frequencies between the schizophrenia and control groups was observed (&#x003c7;<sup>2 </sup>= 35.0, df = 7, <italic>P</italic><sub><italic>corr </italic></sub>= 1.1 &#x000d7; 10<sup>-5</sup>). For the combination of SYN2-1, SYN2-2, and SYN2-4, the estimated frequencies of the T-deletion-G haplotype differed between the schizophrenia (0.570) and controls groups (0.440).</p></sec><sec><title><italic>CPLX2 </italic>polymorphisms in schizophrenia and control groups</title><p>Of the five SNPs in <italic>CPLX2</italic>, rs2247916 (CPLX2-1) is located in the promoter region, rs2243404 (CPLX2-2) is located in the 5'UTR, and the others are located in the intronic regions (Fig. <xref ref-type="fig" rid="F1">1</xref>, Table <xref ref-type="table" rid="T1">1</xref>). We determined the genotypic distributions and allelic frequencies of the SNPs in 154 schizophrenic patients and 133 normal healthy controls by direct sequencing or RFLP analysis. The genotypic distributions and allelic frequencies for <italic>CPLX2 </italic>SNPs are shown in Table <xref ref-type="table" rid="T2">2</xref>. The average allelic frequency of the SNPs was 0.126. Given the equivalent frequency for the susceptible allele, the expected detection power for <italic>CPLX2 </italic>was 0.7445 to 0.8802 based on the multiplicative model with the genotype relative risk = 1.8 to 2.0 [<xref ref-type="bibr" rid="B22">22</xref>]. None of the five SNPs showed any significant deviations from Hardy-Weinberg equilibrium. We observed no significant differences in genotypic distributions or allelic frequencies between the schizophrenia and control groups (Table <xref ref-type="table" rid="T2">2</xref>).</p><p>We compared LD for all possible two-way comparisons of the SNPs in controls (Table <xref ref-type="table" rid="T5">5</xref>). The pairwise D' values for the five SNPs were consistently low, except in one instance (CPLX2-2 <italic>vs</italic>. CPLX2-4; D' = 0.715, r<sup>2 </sup>= 0.011). Only one pair of SNPs (CPLX2-1 <italic>vs</italic>. CPLX2-2) showed a significant haplotype association with schizophrenia (&#x003c7;<sup>2 </sup>= 16.28, df = 3, <italic>P </italic>= 0.0009), even after the Bonferroni correction (n = 10, <italic>P</italic><sub><italic>corr </italic></sub>= 0.009, Table <xref ref-type="table" rid="T5">5</xref>). For the combination of CPLX2-1 &#x02013; CPLX2-2, the G allele-the C allele haplotype was observed more frequently in the schizophrenia group than the control group (Table <xref ref-type="table" rid="T6">6</xref>).</p><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Pairwise linkage disequilibrium and haplotype association of SNPs in <italic>CPLX2</italic>.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><bold>CPLX2-1</bold></td><td align="left"><bold>CPLX2-2</bold></td><td align="left"><bold>CPLX2-3</bold></td><td align="left"><bold>CPLX2-4</bold></td><td align="left"><bold>CPLX2-5</bold></td></tr></thead><tbody><tr><td align="left"><bold>CPLX2-1</bold></td><td></td><td align="left">0.412</td><td align="left">0.325</td><td align="left">0.058</td><td align="left">0.008</td></tr><tr><td></td><td></td><td align="left">0.136</td><td align="left">0.300</td><td align="left">0.001</td><td align="left">0.008</td></tr><tr><td align="left"><bold>CPLX2-2</bold></td><td align="left"><bold>9.0 &#x000d7; 10<sup>-4 a</sup></bold></td><td></td><td align="left">0.309</td><td align="left">0.715</td><td align="left">0.301</td></tr><tr><td></td><td></td><td></td><td align="left">0.042</td><td align="left">0.011</td><td align="left">0.001</td></tr><tr><td align="left"><bold>CPLX2-3</bold></td><td align="left">0.494</td><td align="left">0.056</td><td></td><td align="left">0.027</td><td align="left">0.019</td></tr><tr><td></td><td></td><td></td><td></td><td align="left">0.015</td><td align="left">0.016</td></tr><tr><td align="left"><bold>CPLX2-4</bold></td><td align="left">0.994</td><td align="left">0.830</td><td align="left">0.564</td><td></td><td align="left">0.143</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td align="left">0.000</td></tr><tr><td align="left"><bold>CPLX2-5</bold></td><td align="left">1.000</td><td align="left">0.564</td><td align="left">0.650</td><td align="left">0.992</td><td></td></tr></tbody></table><table-wrap-foot><p>Upper diagonal top: D', bottom: r<sup>2 </sup>in controls; Lower diagonal: <italic>P </italic>value by <italic>&#x003c7;</italic><sup>2 </sup>test (df = 3)</p><p><sup>a </sup><italic>P </italic>&#x0003c; 0.01 after Bonferroni correction</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T6"><label>Table 6</label><caption><p>Estimated haplotype frequencies of the CPLX2-1 &#x02013; CPLX2-2 combination on the <italic>CPLX2</italic></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Haplotypes</bold></td><td></td><td align="left" colspan="2"><bold>Estimated frequency</bold></td></tr></thead><tbody><tr><td align="left"><bold>CPLX2-1</bold></td><td align="left"><bold>CPLX2-2</bold></td><td align="left"><bold>Cases</bold></td><td align="left"><bold>Controls</bold></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">T</td><td align="left">C</td><td align="left">0.010</td><td align="left">0.036</td></tr><tr><td align="left">T</td><td align="left">T</td><td align="left">0.061</td><td align="left">0.047</td></tr><tr><td align="left">G</td><td align="left">C</td><td align="left">0.919</td><td align="left">0.862</td></tr><tr><td align="left">G</td><td align="left">T</td><td align="left">0.010</td><td align="left">0.055</td></tr></tbody></table></table-wrap></sec></sec><sec><title>Discussion</title><p>In this study, we observed significant, pairwise haplotype associations with schizophrenia for two pairs of SNPs in <italic>SYN2 </italic>(SYN2-1 &#x02013; SYN2-2 and SYN2-2 &#x02013; SYN2-4; <italic>P</italic><sub><italic>corr </italic></sub>= 9.35 &#x000d7; 10<sup>-5 </sup>and <italic>P</italic><sub><italic>corr </italic></sub>= 0.019, respectively) and one pair of SNPs in <italic>CPLX2 </italic>(CPLX2-1 &#x02013; CPLX2-2, <italic>P</italic><sub><italic>corr </italic></sub>= 0.009) (Table <xref ref-type="table" rid="T3">3</xref>, <xref ref-type="table" rid="T5">5</xref>). The three-way haplotype (SYN2-1, SYN2-2, and SYN2-4) also showed a significant association with schizophrenia (<italic>P</italic><sub><italic>corr </italic></sub>= 1.1 &#x000d7; 10<sup>-5</sup>). The SYN2-1 and CPLX2-1 SNPs are located in the respective promoter regions, -98 and -156. SYN2-1 was located within the GC box motif and CPLX2-1 within the C/EBP motif in a database search <ext-link ext-link-type="uri" xlink:href="http://www.cbrc.jp/research/db/TFSEARCH"/>. The positive haplotype associations seem to be based on an increase of LD in the schizophrenia group compared to the control group because the D' values of the schizophrenia group were higher than those of the controls [(SYN2-1 &#x02013; SYN2-2, 0.935 <italic>vs</italic>. 0.531 (schizophrenics <italic>vs</italic>. controls)), (SYN2-2 &#x02013; SYN2-4, 0.750 <italic>vs</italic>. 0.453)] (Table <xref ref-type="table" rid="T3">3</xref>). A similar situation was also observed with the positive association of the haplotype in <italic>CPLX2 </italic>with schizophrenia [CPLX2-1 &#x02013; CPLX2-2, 0.852 <italic>vs</italic>. 0.412 (schizophrenics <italic>vs</italic>. controls)] (Table <xref ref-type="table" rid="T5">5</xref>).</p><p>Chen <italic>et al</italic>. [<xref ref-type="bibr" rid="B23">23</xref>] recently reported an association study of four SNPs in <italic>SYN2 </italic>using Han Chinese samples. They found significant associations of SNP rs795009 and a haplotype constructed by the four SNPs with schizophrenia. Chen <italic>et al</italic>. [<xref ref-type="bibr" rid="B23">23</xref>] and our study examined two SNPs (rs2308169 and rs308963) in common, and their genotypic and allelic frequencies were similar in both studies. Although Chen <italic>et al</italic>. [<xref ref-type="bibr" rid="B23">23</xref>] did not mention the pairwise haplotype association study that we performed, they did report a significant difference in the overall four-way haplotype frequencies between schizophrenics and controls. Since two independent studies have reported a significant haplotype association of <italic>SYN2 </italic>with schizophrenia, this gene is probably involved in the pathogenesis of schizophrenia.</p><p>Several studies have suggested that the decreased expression of synaptic genes is characteristic of schizophrenia. In the hippocampus of schizophrenic patients, several studies have shown a consistent pattern of decreases in presynaptic proteins and their encoding mRNAs, such as synapsin 2, synaptophysin, and synaptosomal-associated protein-25 (SNAP-25) [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B24">24</xref>]. Furthermore, a reduction in the synapsin 2 mRNA levels was observed in the prefrontal cortex of schizophrenic patients [<xref ref-type="bibr" rid="B14">14</xref>], but controvertible results have also been reported [<xref ref-type="bibr" rid="B25">25</xref>]. The altered expression levels of other presynaptic proteins, complexin 1 and complexin 2, have been reported in schizophrenic patients [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. Interestingly, complexin 1 is enriched in axosomatic regions, inhibitor neurons, and their synapses, while complexin 2 is enriched in the axodendritic terminals [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B26">26</xref>]. The differential expression of complexins 1 and 2 implies their involvement in the excitatory synapse in the hippocampus of schizophrenic patients [<xref ref-type="bibr" rid="B11">11</xref>]. These observations suggest that abnormal expression of <italic>SYN2 </italic>and <italic>CPLX2 </italic>may cause the vulnerability to schizophrenia by altering neurotransmitter release and neuroplasticity.</p></sec><sec><title>Conclusion</title><p>We found significant differences in the haplotype frequencies in both <italic>SYN2 </italic>and <italic>CPLX2 </italic>polymorphisms between schizophrenia and control groups. In addition, the haplotype constructed from three polymorphisms (SYN2-1, SYN2-2, and SYN2-4) showed a significant association with schizophrenia. Our results suggest that both <italic>SYN2 </italic>and <italic>CPLX2 </italic>polymorphisms may contribute susceptibility to schizophrenia in the Korean population.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Subjects</title><p>A total of 154 unrelated Korean schizophrenia patients (80 male and 74 female with a mean &#x000b1; SD age of 43.8 &#x000b1; 11.4 yr) and 133 unrelated Korean controls (64 male and 69 female; age 50.6 &#x000b1; 11.7 yr) were recruited. For the <italic>SYN2 </italic>analysis, 113 unrelated Korean schizophrenia patients (60 male and 53 female with a mean &#x000b1; SD age of 42.2 &#x000b1; 11.3 yr) and 114 unrelated Korean controls (60 male and 54 female; age 51.7 &#x000b1; 10.9 yr) were participated. The schizophrenia patients were diagnosed using the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria. The control subjects were recruited after they had been designated as mentally healthy in a general health check-up program. The average age of the controls exceeded 50 years because we tried to avoid misincorporation of patients with late onset schizophrenia in the control group, while it may produce statistical bias potentially. Written informed consent was obtained from all subjects. This study was approved by the Ethics Committee of Kyung Hee University, Faculty of Medicine. Genomic DNA was extracted from whole blood cells using a NucleoSpin<sup>&#x000ae; </sup>Blood kit (Macherey-Nagel, Easton, PA).</p></sec><sec><title>SNP Selection and PCR-based Genotyping</title><p>Since the genomic sizes of <italic>SYN2 </italic>and <italic>CPLX2 </italic>are about 187 and 89 kb, respectively, we initially intended to select common polymorphisms at intervals of approximately 20&#x02013;50 kb from the dbSNP <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/"/>. After validating the frequency of each polymorphism in 24 healthy Korean individuals using direct sequencing, we selected seven common polymorphisms from <italic>SYN2 </italic>and five from <italic>CPLX2 </italic>for further analyses (Fig. <xref ref-type="fig" rid="F1">1</xref>, Table <xref ref-type="table" rid="T1">1</xref>). We amplified the fragments containing polymorphisms individually and genotyped DNA samples for each SNP with either PCR-based restriction fragment length polymorphism (RFLP) assays or direct sequencing performed with an ABI PRISM<sup>&#x000ae; </sup>Dye Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, CA) on an ABI PRISM<sup>&#x000ae; </sup>3100 DNA sequencer (Applied Biosystems) (Table <xref ref-type="table" rid="T1">1</xref>). In case of unclear sequence data, we repeated direct sequencing under various conditions until the genotype was determined correctly.</p></sec><sec><title>Statistics</title><p>The deviation of the genotypic frequencies from Hardy-Weinberg equilibrium was examined using the chi-square test (df = 1). Statistical differences in the genotypic distributions and allelic frequencies between the schizophrenia and control groups were examined using the Fisher's exact probability test. We calculated D' and r<sup>2 </sup>to evaluate the magnitude of linkage disequilibrium (LD) [<xref ref-type="bibr" rid="B19">19</xref>]. We estimated haplotype frequencies using the EH program, version 1.14 [<xref ref-type="bibr" rid="B20">20</xref>]. The statistical analysis of haplotype association was done as previously described [<xref ref-type="bibr" rid="B21">21</xref>]. We applied the Bonferroni correction to multiple testing based on the number of haplotypes. The significance level for all the statistical tests was 0.05.</p></sec></sec><sec><title>Authors' contributions</title><p>HJ Lee conceived of the study, carried out sequencing, participated in the interpretation of the data and drafted manuscript, JY Song, JW Kim and JK Park recruited the samples of schizophrenia patients, SY Jin, MS Hong, and J-H Chung recruited the samples of normal control, H Shibata and Y Fukumaki participated in its design, carried out the statistical analyses, and participated in the interpretation of data. All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was supported by JPSS and KOSEF, and in part by a grant of the Korean Health 21 R&#x00026;D Project, Ministry of Health &#x00026; Welfare, Republic of Korea. (0405-NS01-0704-0001).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>DA</given-names></name><name><surname>Lieberman</surname><given-names>JA</given-names></name></person-group><article-title>Catching up on schizophrenia: natural history and neurobiology</article-title><source>Neuron</source><year>2002</year><volume>28</volume><fpage>325</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">11144342</pub-id><pub-id pub-id-type="doi">10.1016/S0896-6273(00)00111-2</pub-id></citation></ref><ref id="B2"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Owen</surname><given-names>MJ</given-names></name><name><surname>O'Donovan</surname><given-names>MC</given-names></name><name><surname>Gottesman</surname><given-names>II</given-names></name></person-group><person-group person-group-type="editor"><name><surname>McGuffin P, Owen MJ, Gottesman II</surname></name></person-group><article-title>Schizophrenia</article-title><source>Psychiatric Genetics &#x00026; Genomics</source><year>2002</year><publisher-name>Oxford</publisher-name><fpage>247</fpage><lpage>266</lpage></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Owen</surname><given-names>MJ</given-names></name><name><surname>Williams</surname><given-names>NM</given-names></name><name><surname>O'Donovan</surname><given-names>MC</given-names></name></person-group><article-title>The molecular genetics of schizophrenia: new findings promise new insights</article-title><source>Mol Psychiatry</source><year>2004</year><volume>9</volume><fpage>14</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">14581932</pub-id><pub-id pub-id-type="doi">10.1038/sj.mp.4001444</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frankle</surname><given-names>WG</given-names></name><name><surname>Lerma</surname><given-names>J</given-names></name><name><surname>Laruelle</surname><given-names>M</given-names></name></person-group><article-title>The synaptic hypothesis of schizophrenia</article-title><source>Neuron</source><year>2003</year><volume>39</volume><fpage>205</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">12873379</pub-id><pub-id pub-id-type="doi">10.1016/S0896-6273(03)00423-9</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hilfiker</surname><given-names>S</given-names></name><name><surname>Pieribone</surname><given-names>VA</given-names></name><name><surname>Czernik</surname><given-names>AJ</given-names></name><name><surname>Kao</surname><given-names>H-T</given-names></name><name><surname>Augustine</surname><given-names>GJ</given-names></name><name><surname>Greengard</surname><given-names>P</given-names></name></person-group><article-title>Synapsins as regulators of neurotransmitter release</article-title><source>Phil Trans R Soc Lond B</source><year>1999</year><volume>354</volume><fpage>269</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">10212475</pub-id><pub-id pub-id-type="doi">10.1098/rstb.1999.0378</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kao</surname><given-names>H-T</given-names></name><name><surname>Porton</surname><given-names>B</given-names></name><name><surname>Hilfiker</surname><given-names>S</given-names></name><name><surname>Stefani</surname><given-names>G</given-names></name><name><surname>Pieribone</surname><given-names>VA</given-names></name><name><surname>DeSalle</surname><given-names>R</given-names></name></person-group><article-title>Molecular evolution of the synapsin gene family</article-title><source>J Exp Zool (Mol Dev Evo)</source><year>1999</year><volume>285</volume><fpage>360</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-010X(19991215)285:4&#x0003c;360::AID-JEZ4&#x0003e;3.0.CO;2-3</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tokumaru</surname><given-names>H</given-names></name><name><surname>Umayahara</surname><given-names>K</given-names></name><name><surname>Pellegrini</surname><given-names>LL</given-names></name><name><surname>Ishizuka</surname><given-names>T</given-names></name><name><surname>Saisu</surname><given-names>H</given-names></name><name><surname>Betz</surname><given-names>H</given-names></name></person-group><article-title>SNARE complex oligomerization by synaphin/complexin is essential for synaptic vesicle exocytosis</article-title><source>Cell</source><year>2001</year><volume>104</volume><fpage>421</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">11239399</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(01)00229-X</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Browning</surname><given-names>MD</given-names></name><name><surname>Dudek</surname><given-names>EM</given-names></name><name><surname>Rapier</surname><given-names>JL</given-names></name><name><surname>Leonard</surname><given-names>S</given-names></name><name><surname>Freedman</surname><given-names>R</given-names></name></person-group><article-title>Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics</article-title><source>Biol Psychiatry</source><year>1993</year><volume>34</volume><fpage>529</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">8274580</pub-id><pub-id pub-id-type="doi">10.1016/0006-3223(93)90195-J</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>PJ</given-names></name><name><surname>Eastwood</surname><given-names>SL</given-names></name></person-group><article-title>Preferential involvement of excitatory neurons in medial temporal lobe in schizophrenia</article-title><source>Lancet</source><year>1998</year><volume>352</volume><fpage>1669</fpage><lpage>1673</lpage><pub-id pub-id-type="pmid">9853440</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(98)03341-8</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vawter</surname><given-names>MP</given-names></name><name><surname>Thatcher</surname><given-names>L</given-names></name><name><surname>Usen</surname><given-names>N</given-names></name><name><surname>Hyde</surname><given-names>TM</given-names></name><name><surname>Kleinman</surname><given-names>JE</given-names></name><name><surname>Freed</surname><given-names>WJ</given-names></name></person-group><article-title>Reduction of synapsin in the hippocampus of patients with bipolar disorder and schizophrenia</article-title><source>Mol Psychiatry</source><year>2002</year><volume>7</volume><fpage>571</fpage><lpage>578</lpage><pub-id pub-id-type="pmid">12140780</pub-id><pub-id pub-id-type="doi">10.1038/sj.mp.4001158</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eastwood</surname><given-names>SL</given-names></name><name><surname>Harrison</surname><given-names>PJ</given-names></name></person-group><article-title>Hippocampal synaptic pathology in schizophrenia, bipolar disorder and major depression: a study of complexin mRNAs</article-title><source>Mol Psychiatry</source><year>2000</year><volume>5</volume><fpage>425</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">10889554</pub-id><pub-id pub-id-type="doi">10.1038/sj.mp.4000741</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eastwood</surname><given-names>SL</given-names></name><name><surname>Cotter</surname><given-names>D</given-names></name><name><surname>Harrison</surname><given-names>PJ</given-names></name></person-group><article-title>Cerebellar synaptic protein expression in schizophrenia</article-title><source>Neuroscience</source><year>2001</year><volume>105</volume><fpage>219</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">11483314</pub-id><pub-id pub-id-type="doi">10.1016/S0306-4522(01)00141-5</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knable</surname><given-names>MB</given-names></name><name><surname>Barci</surname><given-names>BM</given-names></name><name><surname>Webster</surname><given-names>MJ</given-names></name><name><surname>Meador-Woodruff</surname><given-names>L</given-names></name><name><surname>Torrey</surname><given-names>EF</given-names></name></person-group><article-title>Molecular abnormalities of hippocampus in severe psychiatry illness: postmortem findings from the Stanley Neuropathology Consortium</article-title><source>Mol Psychiatry</source><year>2004</year><volume>9</volume><fpage>609</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">14708030</pub-id><pub-id pub-id-type="doi">10.1038/sj.mp.4001471</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mirnics</surname><given-names>K</given-names></name><name><surname>Middleton</surname><given-names>FA</given-names></name><name><surname>Marquez</surname><given-names>A</given-names></name><name><surname>Lewis</surname><given-names>DA</given-names></name><name><surname>Levitt</surname><given-names>P</given-names></name></person-group><article-title>Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex</article-title><source>Neuron</source><year>2000</year><volume>28</volume><fpage>53</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">11086983</pub-id><pub-id pub-id-type="doi">10.1016/S0896-6273(00)00085-4</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karlin</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Gentles</surname><given-names>AJ</given-names></name><name><surname>Cleary</surname><given-names>M</given-names></name></person-group><article-title>Associations between human disease genes and overlapping gene groups and multiple amino acid runs</article-title><source>Proc Nat Acad Sci</source><year>2002</year><volume>99</volume><fpage>17008</fpage><lpage>17013</lpage><pub-id pub-id-type="pmid">12473749</pub-id><pub-id pub-id-type="doi">10.1073/pnas.262658799</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>CM</given-names></name><name><surname>Levinson</surname><given-names>DF</given-names></name><name><surname>Wise</surname><given-names>LH</given-names></name><name><surname>DeLisi</surname><given-names>LE</given-names></name><name><surname>Straub</surname><given-names>RE</given-names></name><name><surname>Hovatta</surname><given-names>I</given-names></name></person-group><article-title>Genome scan meta-analysis of schizophrenia and bipolar disorder, Part II: Schizophrenia</article-title><source>Am J Hum Genet</source><year>2003</year><volume>73</volume><fpage>34</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">12802786</pub-id><pub-id pub-id-type="doi">10.1086/376549</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pulver</surname><given-names>AE</given-names></name><name><surname>Lasseter</surname><given-names>K</given-names></name><name><surname>Kasch</surname><given-names>L</given-names></name><name><surname>Wolyniec</surname><given-names>P</given-names></name><name><surname>Nestadt</surname><given-names>G</given-names></name><name><surname>Blouin</surname><given-names>JL</given-names></name></person-group><article-title>Schizophrenia: a genome scan targets chromosomes 3p and 8p as potential sites of susceptibility genes</article-title><source>Am J Med Genet</source><year>1995</year><volume>60</volume><fpage>252</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">7573181</pub-id><pub-id pub-id-type="doi">10.1002/ajmg.1320600316</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sklar</surname><given-names>P</given-names></name><name><surname>Pato</surname><given-names>MT</given-names></name><name><surname>Kirby</surname><given-names>A</given-names></name><name><surname>Kirby</surname><given-names>A</given-names></name><name><surname>Petryshen</surname><given-names>TL</given-names></name><name><surname>Medeiros</surname><given-names>H</given-names></name><name><surname>Carvalho</surname><given-names>C</given-names></name></person-group><article-title>Genome-wide scan in Portuguese island families identifies 5q31-5q35 as a susceptibility locus for schizophrenia</article-title><source>Mol Psychiatry</source><year>2004</year><volume>9</volume><fpage>213</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">14699422</pub-id><pub-id pub-id-type="doi">10.1038/sj.mp.4001418</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taillon-Miller</surname><given-names>P</given-names></name><name><surname>Bauer-Sardina</surname><given-names>I</given-names></name><name><surname>Saccone</surname><given-names>NL</given-names></name><name><surname>Putzel</surname><given-names>J</given-names></name><name><surname>Laitinen</surname><given-names>T</given-names></name><name><surname>Cao</surname><given-names>A</given-names></name><name><surname>Kere</surname><given-names>J</given-names></name><name><surname>Pilia</surname><given-names>G</given-names></name><name><surname>Rice</surname><given-names>JP</given-names></name><name><surname>Kwok</surname><given-names>PY</given-names></name></person-group><article-title>Juxtaposed regions of extensive and minimal linkage disequilibrium in human Xq25 and Xq28</article-title><source>Nat Genet</source><year>2000</year><volume>25</volume><fpage>324</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">10888883</pub-id><pub-id pub-id-type="doi">10.1038/77100</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Ott</surname><given-names>J</given-names></name></person-group><article-title>Testing linkage disequilibrium between a disease gene and marker loci</article-title><source>Am J Hum Genet</source><year>1993</year><volume>53</volume><fpage>1170</fpage></citation></ref><ref id="B21"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Sham</surname><given-names>P</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Sham P</surname></name></person-group><article-title>The analysis of allelic association</article-title><source>Statistics in Human Genetics</source><year>1997</year><publisher-name>London: Arnold</publisher-name><fpage>145</fpage><lpage>185</lpage></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohashi</surname><given-names>J</given-names></name><name><surname>Tokunaga</surname><given-names>K</given-names></name></person-group><article-title>The power of genome-wide association studies of complex disease genes: statistical limitations of indirect approaches using SNP markers</article-title><source>J Hum Genet</source><year>2001</year><volume>46</volume><fpage>478</fpage><lpage>482</lpage><pub-id pub-id-type="pmid">11501946</pub-id><pub-id pub-id-type="doi">10.1007/s100380170048</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>He</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>XY</given-names></name><name><surname>Chen</surname><given-names>QY</given-names></name><name><surname>Liu</surname><given-names>XM</given-names></name><name><surname>Gu</surname><given-names>ZZ</given-names></name></person-group><article-title>Positive association between synapsin II and schizophrenia</article-title><source>Biol Psychiatry</source><year>2004</year><volume>56</volume><fpage>177</fpage><lpage>181</lpage><pub-id pub-id-type="pmid">15271586</pub-id><pub-id pub-id-type="doi">10.1016/j.biopsych.2004.05.010</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>PM</given-names></name><name><surname>Egbufoama</surname><given-names>S</given-names></name><name><surname>Vawter</surname><given-names>MP</given-names></name></person-group><article-title>SNAP-25 reduction in the hippocampus of patients with schizophrenia</article-title><source>Prog Neuropsychopharmacol Biol Psychiatry</source><year>2003</year><volume>27</volume><fpage>411</fpage><lpage>417</lpage><pub-id pub-id-type="pmid">12691775</pub-id><pub-id pub-id-type="doi">10.1016/S0278-5846(03)00027-7</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>C</given-names></name><name><surname>Sugai</surname><given-names>T</given-names></name><name><surname>Iritani</surname><given-names>S</given-names></name><name><surname>Niizato</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>R</given-names></name><name><surname>Makifuchi</surname><given-names>T</given-names></name></person-group><article-title>A quantitative study on the expression of synapsin II and N-ethylmaleimide-sensitive fusion protein in schizophrenic patients</article-title><source>NeuroSci Lett</source><year>2001</year><volume>305</volume><fpage>185</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">11403936</pub-id><pub-id pub-id-type="doi">10.1016/S0304-3940(01)01844-4</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Matsuda</surname><given-names>Z</given-names></name><name><surname>Ogawa</surname><given-names>M</given-names></name><name><surname>Yagyu</surname><given-names>K</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name></person-group><article-title>Identification of two highly homologous presynaptic proteins distinctly localized at the dendritic and somatic synapses</article-title><source>FEBS Lett</source><year>1995</year><volume>368</volume><fpage>455</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">7635198</pub-id><pub-id pub-id-type="doi">10.1016/0014-5793(95)00713-J</pub-id></citation></ref></ref-list></back></article> 